Expand ALLO Menu
ALLO MENU

ALLO Stock Summary and Trading Ideas (Allogene Therapeutics | NASDAQ:ALLO)

Charts for Today's Stock Price and Implied Volatility in Allogene Therapeutics

Stock Price & Volume | Full Chart

30-Day Implied Volatility | IV30 Full Chart

Trade Ideas for Best Option Strategies for ALLO by Theoretical Edge and Win Rates

Sentiment

Trading Statistics

Key Ratios

Allogene Therapeutics (ALLO) Frequently Asked Questions

What does Allogene Therapeutics do?

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

What symbol and exchange does Allogene Therapeutics stock trade?

Allogene Therapeutics trades on the NASDAQ stock market under the symbol ALLO.

What is Allogene Therapeutics stock price doing today?

As of April 24, 2024, ALLO stock price declined to $3.04 with 2,030,149 million shares trading.

What is Allogene Therapeutics's Beta?

ALLO has a beta of 2.49, meaning it tends to be more sensitive to market movements. ALLO has a correlation of 0.14 to the broad based SPY ETF.

How much is Allogene Therapeutics worth?

ALLO has a market cap of $514.04 million. This is considered a Small Cap stock.

How much money does Allogene Therapeutics make?

Last quarter Allogene Therapeutics reported $21,000 in Revenue and -$.43 earnings per share. This beat revenue expectation by $1,000 and exceeded earnings estimates by $.02.

What is the highest and lowest price Allogene Therapeutics traded in the last 3 year period?

In the last 3 years, ALLO stock traded as high as $35.88 and as low as $2.23.

What are the top ETFs holding Allogene Therapeutics?

The top ETF exchange traded funds that ALLO belongs to (by Net Assets): XBI, VTI, IWM, VXF, VB.

Is Allogene Therapeutics (ALLO) a good investment?

ALLO has underperformed the market in the last year with a price return of -43.8% while the SPY ETF gained +24.2%. ALLO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -5.3% and -26.0%, respectively, while the SPY returned +4.6% and -2.7%, respectively.

What is the support and resistance for Allogene Therapeutics (ALLO) stock price?

ALLO support price is $3.23 and resistance is $3.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALLO stock will trade within this expected range on the day.